Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1248307.RAGok0vvdcjgbm1DGnGaU5Vuz3LZf30Flb9KscCORwlDE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1248307.RAGok0vvdcjgbm1DGnGaU5Vuz3LZf30Flb9KscCORwlDE130_assertion type Assertion NP1248307.RAGok0vvdcjgbm1DGnGaU5Vuz3LZf30Flb9KscCORwlDE130_head.
- NP1248307.RAGok0vvdcjgbm1DGnGaU5Vuz3LZf30Flb9KscCORwlDE130_assertion description "[Loss of CD52 expression in RS most likely predicts resistance to alemtuzumab therapy, which is frequently used in CLL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1248307.RAGok0vvdcjgbm1DGnGaU5Vuz3LZf30Flb9KscCORwlDE130_provenance.
- NP1248307.RAGok0vvdcjgbm1DGnGaU5Vuz3LZf30Flb9KscCORwlDE130_assertion evidence source_evidence_literature NP1248307.RAGok0vvdcjgbm1DGnGaU5Vuz3LZf30Flb9KscCORwlDE130_provenance.
- NP1248307.RAGok0vvdcjgbm1DGnGaU5Vuz3LZf30Flb9KscCORwlDE130_assertion SIO_000772 25511139 NP1248307.RAGok0vvdcjgbm1DGnGaU5Vuz3LZf30Flb9KscCORwlDE130_provenance.
- NP1248307.RAGok0vvdcjgbm1DGnGaU5Vuz3LZf30Flb9KscCORwlDE130_assertion wasDerivedFrom befree-2016 NP1248307.RAGok0vvdcjgbm1DGnGaU5Vuz3LZf30Flb9KscCORwlDE130_provenance.
- NP1248307.RAGok0vvdcjgbm1DGnGaU5Vuz3LZf30Flb9KscCORwlDE130_assertion wasGeneratedBy ECO_0000203 NP1248307.RAGok0vvdcjgbm1DGnGaU5Vuz3LZf30Flb9KscCORwlDE130_provenance.